All In Biotech

Drug Trial Radar · NCT07870278

A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001)

A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-6255 Monotherapy in Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Nov 13, 2026

Primary completion

Jul 5, 2031

Study completion Jul 7, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat advanced and recurrent endometrial cancer (EC) and ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Recurrent means the cancer came back after treatment. MK-6255 is a trial medicine designed to treat advanced and recurrent EC and OC. This trial is the first time that researchers will give MK-6255 to people. The goals of this trial are to learn about: * The safety of MK-6255 and if participants tolerate it. Tolerate means participants will receive the trial medicine unless they need to stop it due to health problems. * What happens to different dose levels (amounts) of MK-6255 in the body over time.

Conditions

  • Ovarian Neoplasms
  • Endometrial Neoplasms

Interventions

  • MK-6255Biological

    During initial dose escalation, participants will receive MK-6255 one weekly (QW). During Dose Interval Extension, participants will receive target doses every 3 weeks (Q3W).

  • CD8 PET TracerOther

    Participants may receive an optional CD8 PET tracer for exploratory imaging assessments.

  • AcetaminophenDrug

    Participants will receive acetaminophen (or similar antipyretic) as premedication.

  • DiphenhydramineDrug

    Participants will receive diphenhydramine (or similar antihistamine) as premedication.

  • DexamethasoneDrug

    Participants will receive dexamethasone as premedication.

  • TocilizumabBiological

    Participants will receive this rescue medication at the investigator's discretion for treatment of cytokine release syndrome (CRS) after MK-6255 administration.

  • Tocilizumab biosimilarBiological

    Participants will receive this rescue medication at the investigator's discretion for treatment of cytokine release syndrome (CRS) after MK-6255 administration.

  • SiltuximabBiological

    Participants will receive this rescue medication at the investigator's discretion for treatment of cytokine release syndrome (CRS) after MK-6255 administration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience a Dose-limiting Toxicity (DLT) as Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0Time frame: Up to 21 days at each dose level
  2. Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 56 months
  3. Number of participants who discontinue study intervention due to an adverse event (AE)Time frame: Up to approximately 56 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • START New Jersey ( Site 0808)

    East Brunswick, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.